KIYATEC prioritizes accurate ex vivo prediction of patients' response to drug treatment, with a focus on data correlation to human clinical outcomes. The company creates and utilizes live phenotypic 3D cell-based models for drug response profiling and applies them to generate information relevant to preclinical testing, clinical trials and clinical cancer diagnostics applications. By accurately predicting patient drug response without ever exposing actual patients to drugs, KIYATEC will create informed drug selection that minimizes clinical trials' failures and maximizes patient outcomes in the clinic. SNNLive spoke with Matthew Gevaert, Ph.D., CEO of KIYATEC Inc. at SEMDA 2014 Annual Conference in Atlanta, GA.
“At Kiyatec we want to change the conversation between cancer patients and their doctors” begins Dr. Gevaert. He continues, “We’ve transformed the conversation from one that’s trial and error which is now to one where the clinician is really empowered to make a decision about that particular individuals therapy based on data.”
Dr. Gevaert explains, “You’re getting your first opinion from your cells and the doctor then is sort of confirming that by their judgment that our test is actually predictive and we’re working hard to provide the data that’s going to give doctors comfort.” He adds, “We’re giving them one data set that come from that persons cells and it would guide them in a way that they’re not being guided right now.” For more information, check out their website at www.kiyatec.com.
© 2017 Stock News Now
Supported by Superior Web Solutions